Mode
Text Size
Log in / Sign up
Phase 2 Completed N=130 Treatment

Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant

leukemia · Blasts Under 5 Percent of Bone Marrow Nucleated Cells · Myelodysplastic Syndrome (MDS)
Source: ClinicalTrials.gov NCT00796068 ↗
Enrolled (actual)
130
Serious AEs
38.5%
Results posted
Feb 2023
Primary outcomePrimary: Number of Participants With Graft Failure/Rejection — 2; 5 Participants

Summary

This phase II trial studies how well giving treosulfan together with fludarabine phosphate and total-body irradiation (TBI) works in treating patients with hematological cancer who are undergoing umbilical cord blood transplant (UCBT). Giving chemotherapy, such as treosulfan and fludarabine phosphate, and TBI before a donor UCBT helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the stem cells from a related or unrelated donor, that do not exactly match the patient's blood, are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine (CsA) and mycophenolate mofetil (MMF) after the transplant may stop this from happening.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Graft Failure/Rejection
2; 5
PRIMARY
Number of Participants With Secondary Graft Failure
0; 0
PRIMARY
Number of Patients With Non-relapse Mortality (NRM)
7; 6
SECONDARY
Number of Participants Surviving by 1 Year
51; 47
SECONDARY
The Number of Participants Alive at Two-years Follow up.
50; 44
SECONDARY
Non-relapse Mortality
8; 10
SECONDARY
Duration (Days) Until Participants Obtained Platelet Engraftment
31; 31
SECONDARY
Number of Participants With Acute Graft-versus-host Disease (GVHD) Grade II-IV by Day 100
36; 37
SECONDARY
Incidence of Acute or Chronic Graft-versus-host Disease (GVHD)
7; 6
SECONDARY
Incidence of Relapse or Disease Progression
17; 11
SECONDARY
Number of Participants Surviving up to 2 Years Without Disease Progression
37; 41
SECONDARY
Incidence of Clinically Significant Infections
53; 61

Eligibility Criteria

Inclusion Criteria

  • Acute myeloid leukemia/acute lymphoblastic leukemia, including biphenotypic acute leukemia or mixed-lineage leukemia: Must have 25% of normal cellularity for age collected less than one month prior to start of conditioning; patients in which adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the principal investigator prior to enrollment; patients persistently aplastic for greater than one month since completing last chemotherapy are also eligible with principal investigator (PI) approval
  • Myelodysplastic syndrome (MDS): Any 2001 World Health Organization (WHO) classification subtype; refractory anemia with excess blasts (RAEB)-2 patients may proceed directly to transplant, but may also be considered for induction chemotherapy before transplant; patients with >= 20% morphologic marrow blasts require induction therapy to reduce morphologic marrow blasts below 5% before transplant
  • Chronic myelogenous leukemia: All types, except refractory blast crisis; chronic phase patients must have failed or been intolerant to Gleevec or other tyrosine kinase inhibitors
  • Patients = = 70 or Eastern Cooperative Oncology Group (ECOG) 0-1; Lansky (for children) score >= 50
  • Patients > 50 must have Karnofsky performance score >= 70 or ECOG 0-1 and comorbidity index = 35% OR fractional shortening > 22%
  • Adequate pulmonary function defined as absence of oxygen (O2) requirements and one of the following:
  • Diffusion lung capacity for carbon monoxide (DLCO) corrected >= 70% mm Hg
  • DLCO corrected between 60% - 69% mm Hg and partial pressure of oxygen (pO2) >= 70 mm Hg
  • DLCO corrected between 50% - 59% mm Hg and pO2 >= 80 mm Hg
  • Pediatric patients unable to perform pulmonary function tests must have O2 saturation > 92% on room air; may not be on supplemental oxygen
  • Adequate hepatic function; patients with clinical or laboratory evidence of liver disease will be evaluated for the cause of liver disease, its clinical severity in terms of liver function, histology, and the degree of portal hypertension; patients with fulminant liver failure, cirrhosis with evidence of portal hypertension or bridging fibrosis, alcoholic hepatitis, esophageal varices, a history of bleeding esophageal varices, hepatic encephalopathy, or correctable hepatic synthetic dysfunction evidenced by prolongation of the prothrombin time, ascites related to portal hypertension, bacterial or fungal abscess, biliary obstruction, chronic viral hepatitis with total serum bilirubin > 3 mg/dL, and symptomatic biliary disease will be excluded
  • Adequate renal function defined as creatinine = 40 ml/min (pediatrics); all adults with a creatinine > 1.2 or a history of renal dysfunction must have estimated creatinine clearance > 40 ml/min
  • If recent mold infection, e.g., Aspergillus, must be cleared by infectious disease to proceed
  • Prior hematopoietic cell transplant: must be >= 3 months after previous transplant
  • DONOR: Human leukocyte antigen (HLA) matching:
  • Minimum requirement: The cord blood (CB) graft(s) must be matched at a minimum at 4/6 HLA-A, B, DRB1 loci with the recipient; therefore 0-2 mismatches at the A or B or DRB1 loci based on intermediate resolution A, B antigen and DRB1 allele typing for determination of HLA-match is allowed
  • HLA-matching determined by high resolution typing is allowed per institutional guidelines as long as the minimum criteria (above) are met
  • DONOR: Selection of two CB units is mandatory when a single cord blood unit does not meet the following criteria in the table below
  • Match grade
  • 6/6
  • Single unit
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00796068). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search